A 2026 endometrial cancer strategy report covering epidemiology, MMR segmentation, PD-1 and HER2 biology, Phase 3 competition, deal signals and R&D positioning.

A 2026 HR-positive HER2-negative breast cancer strategy report covering epidemiology, ESR1 and CDK4/6 biology, Phase 3 competition, deal signals and portfolio positioning.

CStone Pharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Everest Medicines 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Ascentage Pharma 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Henlius Biotech 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Shanghai Junshi Biosciences 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Sino Biopharmaceutical 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

CSPC Pharmaceutical Group 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

BeiGene 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Orphazyme 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Calliditas Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.